RELATION OF PRO-INFLAMMATORY MARKERS IN MEN AND WOMEN WITH ONE YEAR OUTCOMES AFTER MYOCARDIAL INFARCTION
https://doi.org/10.15829/1728-8800-2015-5-35-39
Abstract
Aim. The evaluation of the prominence of subclinical nonspecific inflammation in men and women with ST-elevation myocardial infarction (STEMI) with different one year outcomes.
Material and methods. Totally 223 patients with STEMI included — 56 (25,1%) women, 167 (74,9%) men. At 10-14 day of hospitalization we checked inflammation factors: interleukins (IL) — 1а, 6, 8, 10, 12, С-reactive protein, tumor necrosis factor, neopterin. In the assessment of inflammatory reaction severity in men and women each group was assessed in general, and further was spread by the age: <65 y.o. and >65 y.o.
Results. In assessment of the combination endpoint it was found that more significantly vascular events developed in women and made up 47% cases, but in men just 33% (р=0,001). Selecting the patients by age-relevant subgroups it was shown that in the age <65 y.o. women had more frequent vascular episodes, than men in this age: 50% (n=20) and 26% (n=89), respectively (р=0,000). In analysis of the IL-12 it is shown than women, comparing to men have this parameter higher in negative as in positive outcome: in positive prognosis 1,4 times higher (р=0,019), and negative prognosis — 1,6 times (р=0,045). In neopterine analysis, depending on combination endpoint it was found than in men with negative outcome the level of neopterin was significantly higher — 17,41 (9,52; 20,90) nmoles/L, than in men with positive outcome — 10,80 (6,53; 10,91) nmoles/L (р=0,000).
Conclusion. Negative prognosis in women with STEMI is associated with the increase of IL-12 by 10-14 day, in men — neopterin. Key words: myocardial infarction, pro-inflammatory markers, gender specifics.
About the Authors
E. V. TavluevaRussian Federation
O. L. Barbarash
Russian Federation
References
1. Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr Med Chem Cardiovasc Hematol Agents 2005; 3 (1): 45-54.
2. Leslee JS, Raffaelle B. Women and Ischemic Heart Disease. JACC 2009; 54: 1561-75.
3. Spence JD, Pilote L. Importance of sex and gender in atherosclerosis and cardiovascular disease. Atherosclerosis 2015; 241(1): 205-7.
4. Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four automated high- sensitive C-reactive protein methods; implications for clinical and epidemiological applications. Clin Chem 2000; 46: 461-8.
5. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007; 93: 1001-7.
6. Singh SK, Suresh MV, Voleti B, et al. The connection between C-reactive protein and atherosclerosis. Ann Med 2008; 40(2): 110-20.
7. Martins TB, Anderson JL, Muhlestein JB, et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol 2006; 125: 906-13.
8. Fuchs D, Avanzas P, Arroyo-Espliguero R, et al. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009; 16: 4644-53.
9. Ray K, Morrow D, Sabatine AM, et al. Long-term prognostic value of neopterin. A novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-8.
10. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, et al. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol 2004; 93: 627-9.
11. Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart 2007; 93: 1537-41.
Review
For citations:
Tavlueva E.V., Barbarash O.L. RELATION OF PRO-INFLAMMATORY MARKERS IN MEN AND WOMEN WITH ONE YEAR OUTCOMES AFTER MYOCARDIAL INFARCTION. Cardiovascular Therapy and Prevention. 2015;14(5):35-39. (In Russ.) https://doi.org/10.15829/1728-8800-2015-5-35-39